InsiderClue
← All stocks

Fulcrum Therapeutics, Inc.

FULC Net selling
CIK 0001680581 #3613 in the set updated 17 Sep 2026
Bought (120 mo)
$51.62M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$66.53M
$0.00 on a plan · $6.09M straight out of an exercise
Sold at will
$60.44M
41 of 69 sales
Net
−$14.91M
−$8.82M against sales at will

By person

22 insiders · 98 transactions
1.0×

Alex C. Sapir holds only 1.0 times base salary in stock. $680.63K of shares against $650.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Alex C. Sapir last reported holding, valued at $3.52, the price Common Stock was last bought or sold at on the open market here, on 17 Jul 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
RA CAPITAL MANAGEMENT, L.P. entity
10% owner
$40.00M (8)
$58.38M (3)
−$18.38M
6,053,960
$21.31M
−57.1%
Gould Robert J
Director
—
$4.94M (29) scheduled
−$4.94M
454,864
$1.60M
−18.4%
Casdin Capital, LLC entity
10% owner
$2.22M (3)
—
+$2.22M
604,285
$2.13M
—
6 Dimensions Capital, L.P. entity
10% owner
$1.90M (1)
—
+$1.90M
559,821
$1.97M
—
Sanofi
10% owner
$1.50M (1)
—
+$1.50M
558,035
$1.96M
—
TANG KEVIN
10% owner
$1.49M (6)
—
+$1.49M
7,080,945
$24.92M
+6.3%
LEVIN MARK J
Director
$1.30M (1)
—
+$1.30M
9,924,404
$34.93M
+58.8%
Third Rock Ventures III, L.P. entity
10% owner
$1.30M (1)
—
+$1.30M
1,962,202
$6.91M
+586.8%
Third Rock Ventures IV, L.P. entity
10% owner
$1.30M (1)
—
+$1.30M
2,343,154
$8.25M
—
Stuart Bryan
See Remarks
—
$1.23M (2) scheduled
−$1.23M
0
$0.00
—
Moxham Christopher
Chief Scientific Officer
—
$911.42K (2) scheduled
−$911.42K
31,071
$109.37K
0.0%
Sapir Alex
See Remarks
$492.03K (1)
—
+$492.03K
193,360
$680.63K
—
Thomson Peter G.
VP Finance & Accounting
$20.70K (1)
$456.33K (8)
−$435.63K
17,512
$61.64K
−55.5%
Wallace Owen B.
Chief Scientific Officer
—
$245.44K (6) scheduled
−$245.44K
133,438
$469.70K
+5.0%
Cadavid Diego
SVP Clinical Development
—
$205.75K (13) scheduled
−$205.75K
65,714
$231.31K
−7.5%
GERAGHTY JAMES A
Director
$91.60K (1)
—
+$91.60K
90,714
$319.31K
+12.4%
Ezekowitz Alan
Director
—
$65.61K (1)
−$65.61K
10,927
$38.46K
−62.2%
Tourangeau Greg
Principal Accounting Officer
—
$62.26K (4)
−$62.26K
14,062
$49.50K
−15.5%
Oltmans Curtis Gale
Chief Legal Officer
$9.80K (1)
$44.60K (1)
−$34.80K
10,252
$36.09K
−18.7%
Morabito Christopher
Chief Medical Officer
$10.08K (1)
—
+$10.08K
1,100
$3.87K
—
GSK plc entity
10% owner
—
—
—
1,785,714
$6.29M
—
Section 32 Fund 2, LP entity
10% owner
—
—
—
464,285
$1.63M
—

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Individual transactions

98
Insider
Date
Role
Action
Shares
Price
Amount
TANG KEVIN
17 Jul 2026
10% owner
Buy indirect
50,945
$3.52
$179.33K
TANG KEVIN
16 Jul 2026
10% owner
Buy indirect
116,671
$3.56
$415.35K
TANG KEVIN
15 Jul 2026
10% owner
Buy indirect
107,377
$3.56
$382.26K
TANG KEVIN
14 Jul 2026
10% owner
Buy indirect
75,952
$3.58
$271.91K
TANG KEVIN
14 Jul 2026
10% owner
Buy indirect
53,651
$3.56
$191.00K
TANG KEVIN
13 Jul 2026
10% owner
Buy indirect
12,966
$3.54
$45.90K
Ezekowitz Alan
26 Jun 2026
Director
Sell
18,000
$3.65
$65.61K
Gould Robert J
2 Feb 2026
Director
Sell
15,000
$10.72
$160.86K
Gould Robert J
2 Jan 2026
Director
Sell
15,000
$11.87
$178.09K
Oltmans Curtis Gale
15 Dec 2025
Chief Legal Officer
Sell
3,452
$12.92
$44.60K
RA CAPITAL MANAGEMENT, L.P.
8 Dec 2025
10% owner
Sell indirect
91,722
$14.98
$1.37M
RA CAPITAL MANAGEMENT, L.P.
8 Dec 2025
10% owner
Sell indirect
2,706,397
$14.28
$38.65M
RA CAPITAL MANAGEMENT, L.P.
8 Dec 2025
10% owner
Sell indirect
1,377,020
$13.33
$18.36M
Gould Robert J
19 Nov 2025
Director
Sell
15,000
$11.03
$165.50K
Tourangeau Greg
8 May 2025
Principal Accounting Officer
Sell
498
$5.06
$2.52K
Sapir Alex
3 Jul 2024
See Remarks
Exercised, kept
150,000
$3.27
$490.50K
Tourangeau Greg
7 May 2024
Principal Accounting Officer
Sell
236
$7.76
$1.83K
Tourangeau Greg
8 Mar 2024
Vice President, Finance
Sell
4,884
$11.72
$57.22K
Sapir Alex
4 Mar 2024
See Remarks
Buy
43,360
$11.35
$492.03K
Tourangeau Greg
10 May 2023
Principal Accounting Officer
Sell
210
$3.31
$695.10
RA CAPITAL MANAGEMENT, L.P.
20 Jan 2023
10% owner
Buy indirect
1,923,076
$13.00
$25.00M
Gould Robert J
13 Jan 2023
Interim President & CEO
Sell
6,766
$15.00
$101.49K
RA CAPITAL MANAGEMENT, L.P.
4 Jan 2023
10% owner
Buy indirect
58,369
$7.80
$455.09K
RA CAPITAL MANAGEMENT, L.P.
4 Jan 2023
10% owner
Buy indirect
122,334
$7.03
$859.71K
RA CAPITAL MANAGEMENT, L.P.
27 Dec 2022
10% owner
Buy indirect
4,089
$5.99
$24.51K
RA CAPITAL MANAGEMENT, L.P.
19 Dec 2022
10% owner
Buy indirect
98,787
$5.90
$582.81K
RA CAPITAL MANAGEMENT, L.P.
16 Dec 2022
10% owner
Buy indirect
1,341,420
$5.42
$7.27M
RA CAPITAL MANAGEMENT, L.P.
15 Dec 2022
10% owner
Buy indirect
237,029
$5.50
$1.30M
RA CAPITAL MANAGEMENT, L.P.
14 Dec 2022
10% owner
Buy indirect
824,600
$5.46
$4.50M
Gould Robert J
7 Jun 2022
Director
Sold after exercise
71,435
$8.09
$577.89K
Gould Robert J
6 Jun 2022
Director
Sold after exercise
24,382
$8.10
$197.59K
Gould Robert J
3 Jun 2022
Director
Sold after exercise
25,551
$7.95
$203.06K
Gould Robert J
2 Jun 2022
Director
Sold after exercise
16,689
$7.92
$132.16K
Gould Robert J
7 Apr 2022
Director
Sold after exercise
5,631
$24.02
$135.23K
Gould Robert J
5 Apr 2022
Director
Sold after exercise
52,552
$24.26
$1.27M
Gould Robert J
4 Apr 2022
Director
Sold after exercise
7,235
$24.02
$173.75K
Gould Robert J
1 Apr 2022
Director
Sold after exercise
34,464
$24.03
$828.16K
Stuart Bryan
11 Aug 2021
See Remarks
Sold after exercise
28,000
$23.75
$665.00K
Stuart Bryan
10 Aug 2021
See Remarks
Sold after exercise
32,000
$17.50
$560.00K
Moxham Christopher
10 Aug 2021
Chief Scientific Officer
Sold after exercise
31,071
$18.00
$559.28K
Moxham Christopher
10 Aug 2021
Chief Scientific Officer
Sold after exercise
20,714
$17.00
$352.14K
GERAGHTY JAMES A
28 Jun 2021
Director
Buy
10,000
$9.16
$91.60K
Thomson Peter G.
28 Jun 2021
VP Finance & Accounting
Buy indirect
2,300
$9.00
$20.70K
Oltmans Curtis Gale
28 Jun 2021
SVP, General Counsel
Buy
1,088
$9.01
$9.80K
Morabito Christopher
28 Jun 2021
Chief Medical Officer
Buy
1,100
$9.16
$10.08K
Gould Robert J
16 Mar 2021
See Remarks
Sell
789
$12.43
$9.81K
Gould Robert J
15 Mar 2021
See Remarks
Sell
9,211
$12.13
$111.77K
Thomson Peter G.
22 Feb 2021
VP Finance & Accounting
Sold after exercise
5,000
$14.72
$73.58K
Gould Robert J
16 Feb 2021
See Remarks
Sell
1,673
$14.56
$24.37K
Gould Robert J
16 Feb 2021
See Remarks
Sell
6,542
$14.19
$92.83K
Thomson Peter G.
21 Jan 2021
VP Finance & Accounting
Sell
6,607
$14.00
$92.50K
Gould Robert J
20 Jan 2021
See Remarks
Sell
10,000
$12.08
$120.83K
Wallace Owen B.
14 Sep 2020
Chief Scientific Officer
Exercised, kept
6,350
$7.84
$49.78K
Gould Robert J
8 Jul 2020
See Remarks
Sell
2,500
$20.00
$50.00K
Wallace Owen B.
8 Jul 2020
Chief Scientific Officer
Sold after exercise
2,951
$20.00
$59.02K
Cadavid Diego
1 Jul 2020
SVP Clinical Development
Sell
1,071
$18.30
$19.60K
Wallace Owen B.
30 Jun 2020
Chief Scientific Officer
Sold after exercise
141
$20.00
$2.82K
Gould Robert J
25 Jun 2020
See Remarks
Sell
2,500
$20.80
$51.99K
Cadavid Diego
25 Jun 2020
SVP Clinical Development
Sold after exercise
1,459
$22.00
$32.10K
Cadavid Diego
10 Jun 2020
SVP Clinical Development
Sold after exercise
401
$22.00
$8.82K
Gould Robert J
9 Jun 2020
See Remarks
Sell
156
$20.00
$3.12K
Cadavid Diego
5 Jun 2020
SVP Clinical Development
Sold after exercise
451
$20.18
$9.10K
Gould Robert J
5 Jun 2020
See Remarks
Sell
3,433
$20.17
$69.25K
Gould Robert J
4 Jun 2020
See Remarks
Sell
1,300
$20.04
$26.06K
Cadavid Diego
4 Jun 2020
SVP Clinical Development
Sold after exercise
226
$20.05
$4.53K
Cadavid Diego
3 Jun 2020
SVP Clinical Development
Sold after exercise
338
$20.18
$6.82K
Gould Robert J
3 Jun 2020
See Remarks
Sell
1,500
$20.13
$30.19K
Gould Robert J
2 Jun 2020
See Remarks
Sell
2,797
$20.00
$55.94K
Cadavid Diego
2 Jun 2020
SVP Clinical Development
Sold after exercise
45
$20.00
$900.00
Gould Robert J
1 Jun 2020
See Remarks
Sell
5
$20.00
$100.00
Gould Robert J
29 May 2020
See Remarks
Sell
1,390
$20.08
$27.91K
Cadavid Diego
29 May 2020
SVP Clinical Development
Sold after exercise
200
$20.04
$4.01K
Wallace Owen B.
28 May 2020
Chief Scientific Officer
Sold after exercise
2,232
$20.00
$44.64K
Gould Robert J
28 May 2020
See Remarks
Sell
1,919
$20.01
$38.39K
Cadavid Diego
28 May 2020
SVP Clinical Development
Sold after exercise
600
$20.00
$12.00K
Wallace Owen B.
27 May 2020
Chief Scientific Officer
Sold after exercise
448
$20.00
$8.96K
Gould Robert J
26 May 2020
See Remarks
Sell
2,500
$20.00
$50.00K
Wallace Owen B.
26 May 2020
Chief Scientific Officer
Sold after exercise
412
$20.00
$8.24K
Cadavid Diego
12 May 2020
SVP Clinical Development
Sold after exercise
1,860
$18.00
$33.48K
Thomson Peter G.
11 May 2020
VP Finance & Accounting
Sell
7,500
$16.00
$120.00K
Cadavid Diego
2 Mar 2020
SVP Clinical Development
Sell
315
$18.13
$5.71K
Cadavid Diego
2 Mar 2020
SVP Clinical Development
Sell
1,828
$17.26
$31.55K
Thomson Peter G.
24 Feb 2020
VP Finance & Accounting
Sell
250
$18.61
$4.65K
Thomson Peter G.
24 Feb 2020
VP Finance & Accounting
Sell
2,102
$17.43
$36.64K
Thomson Peter G.
24 Feb 2020
VP Finance & Accounting
Sell
2,648
$16.18
$42.86K
Wallace Owen B.
19 Feb 2020
Chief Scientific Officer
Sold after exercise
6,088
$20.00
$121.76K
Gould Robert J
19 Feb 2020
See Remarks
Sell
2,500
$20.00
$50.00K
Cadavid Diego
3 Feb 2020
SVP Clinical Development
Sell
2,143
$17.33
$37.14K
Thomson Peter G.
23 Jan 2020
VP Finance & Accounting
Sell
262
$18.05
$4.73K
Thomson Peter G.
23 Jan 2020
VP Finance & Accounting
Sell
4,738
$17.17
$81.37K
LEVIN MARK J
22 Jul 2019
Director
Buy indirect
81,250
$16.00
$1.30M
Casdin Capital, LLC
22 Jul 2019
10% owner
Buy indirect
5,000
$14.50
$72.50K
Casdin Capital, LLC
22 Jul 2019
10% owner
Buy indirect
10,000
$14.50
$145.00K
Casdin Capital, LLC
22 Jul 2019
10% owner
Buy indirect
125,000
$16.00
$2.00M
6 Dimensions Capital, L.P.
22 Jul 2019
10% owner
Buy
118,750
$16.00
$1.90M
Third Rock Ventures III, L.P.
22 Jul 2019
10% owner
Buy
81,250
$16.00
$1.30M
Third Rock Ventures IV, L.P.
22 Jul 2019
10% owner
Buy
81,250
$16.00
$1.30M
Sanofi
22 Jul 2019
10% owner
Buy indirect
93,750
$16.00
$1.50M

What was left out

Form 4 filings counted 183
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 16
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 28
Sales at will 41
Transactions with no price 0
Shares from compensation/vesting 32,104,196
Sales filed before the plan box existed 29
History held since 18 Jul 2019